GI
TVRD

GAMMA Investing’s Tvardi Therapeutics TVRD Stock Holding History

GAMMA Investing’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76 Sell
40
-49
-55% -$154 ﹤0.01% 4117
2026
Q1 		$283 Buy
+89
New +$349 ﹤0.01% 4032

Other funds holding TVRD

DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

GAMMA Investing's TVRD Position: Q2 2026 in Review

GAMMA Investing reduced its Tvardi Therapeutics (TVRD) stake by 55% in Q2 2026, selling an estimated $154 and leaving 40 shares worth $76. The position accounts for ﹤0.01% of the portfolio, ranked #4117.

GAMMA Investing first reported a position in TVRD in Q1 2026 and has held it in 2 quarters since. The position peaked at $283 in Q1 2026. 10 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • GAMMA Investing held 40 shares of Tvardi Therapeutics worth $76 as of Q2 2026.
  • GAMMA Investing sold 49 Tvardi Therapeutics shares in Q2 2026, an estimated $154.
  • Tvardi Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4117 holding.
  • GAMMA Investing first reported a position in Tvardi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • GAMMA Investing's Tvardi Therapeutics position peaked at $283 in Q1 2026.
  • 10 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.